NYSE:ABBV - AbbVie Stock Price, News & Analysis

$66.41
-0.15 (-0.23 %)
(As of 08/21/2019 04:14 AM ET)
Today's Range
$66.33
Now: $66.41
$68.4620
50-Day Range
$62.90
MA: $67.95
$74.96
52-Week Range
$62.66
Now: $66.41
$98.70
Volume12.03 million shs
Average Volume8.03 million shs
Market Capitalization$98.19 billion
P/E Ratio8.40
Dividend Yield6.43%
Beta0.96
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.75 billion
Cash Flow$9.6246 per share
Book Value($5.61) per share

Profitability

Net Income$5.69 billion

Miscellaneous

Employees30,000
Outstanding Shares1,478,484,000
Market Cap$98.19 billion
Next Earnings Date11/1/2019 (Estimated)
OptionableOptionable

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.


AbbVie (NYSE:ABBV) Frequently Asked Questions

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Thursday, June 20th. Shareholders of record on Monday, July 15th will be given a dividend of $1.07 per share on Thursday, August 15th. This represents a $4.28 dividend on an annualized basis and a yield of 6.44%. The ex-dividend date is Friday, July 12th. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its Board of Directors has approved a stock repurchase program on Thursday, December 13th 2018, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 3.8% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its shares are undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) posted its quarterly earnings data on Friday, July, 26th. The company reported $2.26 earnings per share for the quarter, beating the Zacks' consensus estimate of $2.21 by $0.05. The firm had revenue of $8.26 billion for the quarter, compared to analyst estimates of $8.09 billion. AbbVie had a net margin of 12.62% and a negative return on equity of 182.70%. The business's revenue was down .3% on a year-over-year basis. During the same quarter last year, the company earned $2.00 EPS. View AbbVie's Earnings History.

When is AbbVie's next earnings date?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, November 1st 2019. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY19 earnings guidance on Friday, July, 26th. The company provided earnings per share guidance of $8.82-8.92 for the period, compared to the Thomson Reuters consensus estimate of $8.78.

What price target have analysts set for ABBV?

14 Wall Street analysts have issued twelve-month price targets for AbbVie's stock. Their predictions range from $66.61 to $135.00. On average, they expect AbbVie's share price to reach $91.3842 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price. View Analyst Price Targets for AbbVie.

What is the consensus analysts' recommendation for AbbVie?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

Has AbbVie been receiving favorable news coverage?

Media coverage about ABBV stock has been trending positive recently, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. AbbVie earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for AbbVie.

Are investors shorting AbbVie?

AbbVie saw a increase in short interest during the month of July. As of July 15th, there was short interest totalling 44,168,500 shares, an increase of 56.6% from the June 15th total of 28,212,900 shares. Based on an average trading volume of 9,230,000 shares, the days-to-cover ratio is presently 4.8 days. Currently, 3.0% of the shares of the company are sold short. View AbbVie's Current Options Chain.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)

Who are AbbVie's major shareholders?

AbbVie's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.22%), BlackRock Inc. (6.65%), Northern Trust Corp (1.36%), Bank of New York Mellon Corp (1.07%), Nuveen Asset Management LLC (0.65%) and State Farm Mutual Automobile Insurance Co. (0.60%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, Parnassus Investments CA, Bank of Montreal Can, King Luther Capital Management Corp, Conning Inc. and First Trust Advisors LP. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez and William J Chase. View Insider Buying and Selling for AbbVie.

Which institutional investors are buying AbbVie stock?

ABBV stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, BlackRock Inc., Putnam Investments LLC, Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, Man Group plc, Panagora Asset Management Inc. and Mackenzie Financial Corp. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Jeffrey Ryan Stewart, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $66.41.

How big of a company is AbbVie?

AbbVie has a market capitalization of $98.19 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.

What is AbbVie's official website?

The official website for AbbVie is http://www.abbvie.com/.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.


MarketBeat Community Rating for AbbVie (NYSE ABBV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  947 (Vote Outperform)
Underperform Votes:  635 (Vote Underperform)
Total Votes:  1,582
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2019 by MarketBeat.com Staff

Featured Article: No Load Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel